Candel Therapeutics Showcases Positive Clinical Trial Data for CAN-2409 in Cancer Immunotherapy
I'm PortAI, I can summarize articles.
Candel Therapeutics Inc. has announced positive results from a phase 3 clinical trial of its candidate CAN-2409 for prostate cancer, along with favorable data from phase 2a trials for pancreatic and lung cancers. The company has $87 million in cash and a loan facility of up to $130 million. Upcoming clinical milestones for various cancers are also highlighted in their corporate presentation.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments